[
    [
        {
            "time": "2021-11-01",
            "original_text": "子公司业绩拖累，长春高新被汇金、全国社保基金减持，盈利能力下降",
            "features": {
                "keywords": [
                    "长春高新",
                    "汇金",
                    "社保基金",
                    "减持",
                    "盈利能力下降"
                ],
                "sentiment_score": -0.7,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "negative",
                "affected_by_time_series": "true",
                "ts_effect_direction": "negative"
            },
            "scores": {
                "News_content": "子公司业绩拖累，长春高新被汇金、全国社保基金减持，盈利能力下降",
                "Correlation": 10,
                "Sentiment": 2,
                "Importance": 9,
                "Impact": 8,
                "Duration": 7,
                "Entity_Density": 9,
                "Market_Scope": 5,
                "Time_Proximity": 6,
                "Headline_Structure": 8,
                "Source_Recency": 7
            }
        },
        {
            "time": "2021-11-01",
            "original_text": "长春高新：董事、总经理姜云涛于2021年11月1日增持1.02万股",
            "features": {
                "keywords": [
                    "长春高新",
                    "姜云涛",
                    "增持",
                    "1.02万股"
                ],
                "sentiment_score": 0.6,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "长春高新：董事、总经理姜云涛于2021年11月1日增持1.02万股",
                "Correlation": 9,
                "Sentiment": 7,
                "Importance": 6,
                "Impact": 5,
                "Duration": 4,
                "Entity_Density": 10,
                "Market_Scope": 3,
                "Time_Proximity": 5,
                "Headline_Structure": 6,
                "Source_Recency": 6
            }
        },
        {
            "time": "2021-11-01",
            "original_text": "东莞证券维持长春高新推荐评级，2021三季报点评：生长激素增长良好，疫苗业务暂时受阻",
            "features": {
                "keywords": [
                    "长春高新",
                    "东莞证券",
                    "生长激素",
                    "疫苗",
                    "增长良好",
                    "暂时受阻"
                ],
                "sentiment_score": 0.4,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "东莞证券维持长春高新推荐评级，2021三季报点评：生长激素增长良好，疫苗业务暂时受阻",
                "Correlation": 9,
                "Sentiment": 6,
                "Importance": 7,
                "Impact": 6,
                "Duration": 6,
                "Entity_Density": 9,
                "Market_Scope": 4,
                "Time_Proximity": 7,
                "Headline_Structure": 7,
                "Source_Recency": 7
            }
        },
        {
            "time": "2021-11-01",
            "original_text": "国金证券维持长春高新买入评级：金赛药业增长强劲，产品线持续丰富",
            "features": {
                "keywords": [
                    "长春高新",
                    "国金证券",
                    "金赛药业",
                    "增长强劲",
                    "产品线丰富"
                ],
                "sentiment_score": 0.8,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "国金证券维持长春高新买入评级：金赛药业增长强劲，产品线持续丰富",
                "Correlation": 10,
                "Sentiment": 8,
                "Importance": 8,
                "Impact": 7,
                "Duration": 7,
                "Entity_Density": 9,
                "Market_Scope": 5,
                "Time_Proximity": 7,
                "Headline_Structure": 8,
                "Source_Recency": 7
            }
        },
        {
            "time": "2021-11-01",
            "original_text": "长春高新2021年三季报点评：生长激素市场空间广阔，金赛业绩持续高增长【东吴医药朱国广团队】",
            "features": {
                "keywords": [
                    "长春高新",
                    "三季报",
                    "生长激素",
                    "市场空间广阔",
                    "金赛业绩高增长"
                ],
                "sentiment_score": 0.9,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "长春高新2021年三季报点评：生长激素市场空间广阔，金赛业绩持续高增长【东吴医药朱国广团队】",
                "Correlation": 10,
                "Sentiment": 8,
                "Importance": 9,
                "Impact": 8,
                "Duration": 8,
                "Entity_Density": 10,
                "Market_Scope": 5,
                "Time_Proximity": 7,
                "Headline_Structure": 9,
                "Source_Recency": 8
            }
        }
    ]
]